449 related articles for article (PubMed ID: 25915427)
41. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
Agnihotri S; Gugel I; Remke M; Bornemann A; Pantazis G; Mack SC; Shih D; Singh SK; Sabha N; Taylor MD; Tatagiba M; Zadeh G; Krischek B
J Neurosurg; 2014 Dec; 121(6):1434-45. PubMed ID: 25245477
[TBL] [Abstract][Full Text] [Related]
42. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
Montero JC; López-Pérez R; San Miguel JF; Pandiella A
Haematologica; 2008 Jun; 93(6):851-9. PubMed ID: 18443272
[TBL] [Abstract][Full Text] [Related]
43. Apoptosis of human prostate cancer cells induced by marine actinomycin X2 through the mTOR pathway compounded by MiRNA144.
Liu J; Xie S; Wu Y; Xu M; Ao C; Wang W; Zeng Q; Hu W; Li M
Anticancer Drugs; 2016 Mar; 27(3):156-63. PubMed ID: 26645890
[TBL] [Abstract][Full Text] [Related]
44. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
45. Resveratrol Increases Anti-Proliferative Activity of Bestatin Through Downregulating P-Glycoprotein Expression Via Inhibiting PI3K/Akt/mTOR Pathway in K562/ADR Cells.
Wang L; Wang C; Jia Y; Liu Z; Shu X; Liu K
J Cell Biochem; 2016 May; 117(5):1233-9. PubMed ID: 26460589
[TBL] [Abstract][Full Text] [Related]
46. Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.
Han K; Xu X; Chen G; Zeng Y; Zhu J; Du X; Zhang Z; Cao B; Liu Z; Mao X
J Hematol Oncol; 2014 Jan; 7():9. PubMed ID: 24428908
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by repressing KLF4/PI3K/Akt/p21 pathway.
Chang YL; Zhou PJ; Wei L; Li W; Ji Z; Fang YX; Gao WQ
Oncotarget; 2015 Sep; 6(27):24017-31. PubMed ID: 26172296
[TBL] [Abstract][Full Text] [Related]
48. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.
Fuka G; Kantner HP; Grausenburger R; Inthal A; Bauer E; Krapf G; Kaindl U; Kauer M; Dworzak MN; Stoiber D; Haas OA; Panzer-Grümayer R
Leukemia; 2012 May; 26(5):927-33. PubMed ID: 22094587
[TBL] [Abstract][Full Text] [Related]
49. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
50. [Phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway is critical for survival and proliferation of pancreatic cancer stem-like side population cells].
Zhou J; Wang CY; Liu T; Wu HS; Zhou F; Xiong JX; Zhao G; Yang M; Yin T; Zhou MT
Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2994-8. PubMed ID: 19080079
[TBL] [Abstract][Full Text] [Related]
51. Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway.
Wang X; Ren JH; Lin F; Wei JX; Long M; Yan L; Zhang HZ
Cancer Biol Ther; 2010 Sep; 10(6):632-43. PubMed ID: 20657188
[TBL] [Abstract][Full Text] [Related]
52. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H
Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563
[No Abstract] [Full Text] [Related]
53. Inactivated Sendai virus induces apoptosis and autophagy via the PI3K/Akt/mTOR/p70S6K pathway in human non-small cell lung cancer cells.
Zhang Q; Zhu H; Xu X; Li L; Tan H; Cai X
Biochem Biophys Res Commun; 2015 Sep; 465(1):64-70. PubMed ID: 26235873
[TBL] [Abstract][Full Text] [Related]
54. The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.
Rao E; Jiang C; Ji M; Huang X; Iqbal J; Lenz G; Wright G; Staudt LM; Zhao Y; McKeithan TW; Chan WC; Fu K
Leukemia; 2012 May; 26(5):1064-72. PubMed ID: 22116552
[TBL] [Abstract][Full Text] [Related]
55. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
57. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.
Harvey RD; Lonial S
Future Oncol; 2007 Dec; 3(6):639-47. PubMed ID: 18041916
[TBL] [Abstract][Full Text] [Related]
58. [Study of gambogenic acid-induced apoptosis of melanoma B16 cells through PI3K/Akt/mTOR signaling pathways].
Cheng H; Zhang X; Su JJ; Li QL
Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1666-9. PubMed ID: 25095381
[TBL] [Abstract][Full Text] [Related]
59. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells.
Lau MT; Leung PC
Cancer Lett; 2012 Dec; 326(2):191-8. PubMed ID: 22922215
[TBL] [Abstract][Full Text] [Related]
60. Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma.
Dou R; Qian J; Wu W; Zhang Y; Yuan Y; Guo M; Wei R; Yang S; Jurczyszyn A; Janz S; Beksac M; Gu C; Yang Y
Cell Death Dis; 2021 Feb; 12(2):206. PubMed ID: 33627630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
